| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 07/28/2005 | US20050164165 Probe specific identification/classification of hepatitis c variants; genomics; reverse transcription and viral genotyping |
| 07/28/2005 | US20050164164 Hiv-1 virus tat-protein mutants |
| 07/28/2005 | US20050164163 Helicase inhibitors; enzyme inhibitor; viricides agent; mimetics |
| 07/28/2005 | US20050164162 Methods for multiple parameters screening and evolution of cells to produce small molecules with multiple functionalities |
| 07/28/2005 | US20050164161 Electrical field stimulation of eukaryotic cells |
| 07/28/2005 | US20050163844 Controlled and sustained delivery of nucleic acid-based therapeutic agents |
| 07/28/2005 | US20050163832 liposome, safe and efficient delivery of agents, i.e. proteins, nucleic acids, small molecules and/or other drugs, into cell of higher organism in vitro or in vivo; transducing polypeptide-lipid vesicle complex; protein transduction domain of HIV-1 TAT protein, VP22 herpes virus or Antennapedia protein |
| 07/28/2005 | US20050163805 Orthopoxvirus vectors, genes and products thereof |
| 07/28/2005 | US20050163804 Containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus; Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses |
| 07/28/2005 | US20050163796 Decapeptide immunogen able inducing cytotoxic lymphocytes, is used to provide a protection against an HIV infection; biodrugs |
| 07/28/2005 | US20050163794 Immunological herpes simplex virus antigens and methods for use thereof |
| 07/28/2005 | US20050163792 Stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen |
| 07/28/2005 | US20050163791 Brachyspira hyodysenteriae vaccine |
| 07/28/2005 | US20050163788 Prevention and treatment of amyloidogenic disease |
| 07/28/2005 | US20050163786 Compounds and methods for modulating adhesion molecule function |
| 07/28/2005 | US20050163783 polypeptide dimers having at least four binding sites and at least two polypeptide chains linked via at least one interchain disulfide linkage; IgG3 hinge domain |
| 07/28/2005 | US20050163782 polypeptide dimers having at least four binding sites and at least two polypeptide chains linked via at least one interchain disulfide linkage; IgG3 hinge domain |
| 07/28/2005 | US20050163781 uses of inhibitors against hypoxia-induced genes for the manufacture of a medicament to prevent and/or to suppress post-operative/post-wounding adhesions formation; peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma |
| 07/28/2005 | US20050163776 Treatment of tse infection |
| 07/28/2005 | US20050163773 Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity |
| 07/28/2005 | US20050163772 B7S1: an immune modulator |
| 07/28/2005 | US20050163770 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 07/28/2005 | US20050163767 useful as a diagnostic marker or a drug target for bronchial asthma, chronic obstructive pulmonary disease; isolated antibody which specifically binds to a specific protein belonging to the chitinase family |
| 07/28/2005 | US20050163762 activating auto-antigen specific T cells such as AChR-specific T cells in an auto-immune disease patient such as myasthenia gravis; virus for transferring genes to antigen presenting cells so that they express, process, and present an antigen which will stimulate antigen-specific T cells |
| 07/28/2005 | US20050163758 Tumor/cancer therapy/drugs for infecting/killing cells with mutant virus; comprises deletion or inactivating mutation in both copies of gene, at least one copy is reintroduced under transcriptional control of cell-specific and/or tumor-specific promoter; capable of delivering transgene cytotoxic to tumor |
| 07/28/2005 | US20050163757 Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics |
| 07/28/2005 | US20050163756 expressing a gene product in the gut of an animal by orally administering a recombinant AAV vector; effective, long-term expression systems; lactase deficiency |
| 07/28/2005 | US20050163755 Methods and compositions related to 1-caldesmon |
| 07/28/2005 | US20050163754 Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
| 07/28/2005 | US20050163753 Stable adenoviral vectors and methods for propagation thereof |
| 07/28/2005 | US20050163747 Heteromultimeric TNF ligand family members |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163709 Development of DNA probes and immunological reagents specific for cell surface-expressed molecules and transformation-associated genes |
| 07/28/2005 | US20050161399 LC/MS method of analyzing high molecular weight proteins |
| 07/28/2005 | US20050161377 comprising cartridges having filters, compressors for supplying compressed air, pumps and passageway having valves, used for separation of nucleic acids from sample liquids |
| 07/28/2005 | US20050161331 loading molecules into matrices, then applying an assymetric electric field to separate the molecules according to size and collecting the separated molecules at locations along the matrices |
| 07/28/2005 | US20050161056 Modifying nicotine and nitrosamine levels in tobacco |
| 07/28/2005 | EP1573636A3 System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of peak data from an automated sequencer |
| 07/28/2005 | DE10360483A1 Expressionsvektor und dessen Verwendung Expression vector and its use |
| 07/28/2005 | DE10359660A1 Psod-Expressionseinheiten Psod expression units |
| 07/28/2005 | DE10359595A1 Pgro-Expressionseinheiten Pgro expression units |
| 07/28/2005 | DE10359594A1 PEF-TU-Expressionseinheiten PEF-TU-expression units |
| 07/28/2005 | DE10358077A1 Verfahren zur Erhöhung der Sensitivität von Tumorzellen A method for increasing the sensitivity of tumor cells |
| 07/28/2005 | DE102004059633A1 Promotoren und deren Verwendung Promoters and their use |
| 07/28/2005 | DE10116101B4 Nukleinsäurekonstrukt und Mikroorganismus mit die Sulfitbildung erhöhenden Sequenzen Nucleic acid construct and microorganism with the sulphite-increasing sequences |
| 07/28/2005 | CA2852122A1 Novel culture systems for ex vivo development |
| 07/28/2005 | CA2559352A1 Lipid compositions and use thereof |
| 07/28/2005 | CA2554001A1 Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same |
| 07/28/2005 | CA2553995A1 Method for obtaining a singular cell model capable of reproducing in vitro the metabolic idiosyncrasy of humans |
| 07/28/2005 | CA2553947A1 Promoter |
| 07/28/2005 | CA2553807A1 Generation of specific adhesion in gram-negative bacteria by means of anchoring immunoglobulin single domains on their surface with autotransporters |
| 07/28/2005 | CA2553790A1 Differentiation regulating agent containing gene regulating differentiation from stem cells into natural killer cells as effective ingredient |
| 07/28/2005 | CA2553594A1 Particle-induced ghrelin immune response |
| 07/28/2005 | CA2553377A1 Gene therapy for tumors using minus-strand rna viral vectors encoding immunostimaulatory cytokines |
| 07/28/2005 | CA2553336A1 Integrase fusion proteins and their use with integrating gene therapy |
| 07/28/2005 | CA2553261A1 Immunokinases |
| 07/28/2005 | CA2552947A1 Chimera botulinum toxin type e |
| 07/28/2005 | CA2552750A1 M-csf-specific monoclonal antibody and uses thereof |
| 07/28/2005 | CA2552505A1 Novel carotenoid hydroxylases for use in engineering carotenoid metabolism in plants |
| 07/28/2005 | CA2552288A1 Novel culture systems for ex vivo development |
| 07/28/2005 | CA2551921A1 Melon plants producing fruits with high acid and sugar content |
| 07/28/2005 | CA2551462A1 Methods for nucleic acid isolation and kits using solid phase material |
| 07/28/2005 | CA2551453A1 Methods for nucleic acid isolation and kits using a microfluidic device and concentration step |
| 07/28/2005 | CA2551392A1 Methods of expressing heterologous protein in plant seeds using monocot non seed-storage protein promoters |
| 07/28/2005 | CA2551156A1 Methods for nucleic acid isolation and kits using a microfluidic device and sedimenting reagent |
| 07/28/2005 | CA2551126A1 Toxin complex proteins and genes from xenorhabdus bovienii |
| 07/28/2005 | CA2547511A1 Recombinant icosahedral virus like particle production in pseudomonads |
| 07/28/2005 | CA2546319A1 Production of glucagon like peptide 2 and analogs |
| 07/27/2005 | WO2005067410A2 Synthetic nucleic acids from aquatic species |
| 07/27/2005 | EP1557475A1 Storage of genetic information |
| 07/27/2005 | EP1557468A2 Vector for the production of transplastomic angiosperm plants |
| 07/27/2005 | EP1557467A1 Expression system derived from the lipase regulation cascade of Pseudomonas alcaligenes |
| 07/27/2005 | EP1557466A1 Tumor antigen protein and utilization thereof |
| 07/27/2005 | EP1557465A1 Cap-binding protein |
| 07/27/2005 | EP1557464A1 De novo enzymatic production of nucleic acid molecules |
| 07/27/2005 | EP1557432A2 Hybrid proteins which form heterodimers |
| 07/27/2005 | EP1557431A1 Assay and reagents for quantifying hBNP |
| 07/27/2005 | EP1557428A1 Antibodies against a human stromal derived factor (SDF) and pharmaceutical composition containing them |
| 07/27/2005 | EP1557427A2 Hedgehog protein conjugate |
| 07/27/2005 | EP1557424A1 Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| 07/27/2005 | EP1557178A1 Use of sglt homolog |
| 07/27/2005 | EP1557173A1 Soluble CTLA4 mutant molecules and uses thereof |
| 07/27/2005 | EP1557085A1 Mouse model for human psoriasis |
| 07/27/2005 | EP1557084A2 Method of producing recombinant proteins in the mammary gland of non-transgenic mammals |
| 07/27/2005 | EP1556520A2 Qualitative differential screening for the detection of rna splice sites |
| 07/27/2005 | EP1556513A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 07/27/2005 | EP1556510A2 Oligonucleotide analogues for detecting and analyzing nucleic acids |
| 07/27/2005 | EP1556509A2 Antisense modulation of vegf co-regulated chemokine-1 expression |
| 07/27/2005 | EP1556508A2 Antibodies and methods for generating genetically altered antibodies with high affinity |
| 07/27/2005 | EP1556496A2 Method for inserting a nucleic acid of interest into a prokaryotic or eukaryotic cell by homologous recombination |
| 07/27/2005 | EP1556495A1 Ppr peptide sequences capable of restoring male fertility of plants bearing a male sterility-inducing cytoplasm |
| 07/27/2005 | EP1556493A1 Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |
| 07/27/2005 | EP1556492A2 Antifreeze proteins isolated from forage grasses and methods for their use |
| 07/27/2005 | EP1556491A2 Herbicide-resistant plants, and polynucleotides and methods for providing same |
| 07/27/2005 | EP1556490A2 Novel nucleic acids and polypeptides |
| 07/27/2005 | EP1556489A1 Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity |
| 07/27/2005 | EP1556488A2 Hf-chondroosteomodulin, production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases |
| 07/27/2005 | EP1556487A2 Transplantable cell |
| 07/27/2005 | EP1556486A2 Effective and stable dna enzymes |
| 07/27/2005 | EP1556485A2 Reversible, parallel and multitask cloning method and kit |